Trials of antiplatelet drugs: some methodological considerations.
D001241:Aspirin / Q000627:therapeutic use; D002545:Brain Ischemia / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D003327:Coronary Disease / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control*; D010919:Placebos; D010974:Platelet Aggregation / Q000187:drug effects*; D011897:Random Allocation; D012107:Research Design / Q000592:standards; D013442:Sulfinpyrazone / Q000627:therapeutic use
D010919:Placebos; D001241:Aspirin; D013442:Sulfinpyrazone